Test/js/htmledit/kindeditor/attached/20220721/20220721105135_95073.pdf

What is Chemiluminescent Immunoassay Chemiluminescent immunoassay (CLIA) is an immunoassay technique where the label, i.e. the true “indicator” of the analytic reaction, is a luminescent molecule. In general, luminescence is the emission of visible or near-visible radiation which is generated when an electron transition from an excited state to a ground state. The resultant potential energy in the atom gets released in the form of light. (Cinquanta, Fontana and Bizzaro, 2017) Chemiluminescent immunoassays offer one of the best solutions for the quantification of low concentrations of specific analytes from a complex mixture for in vitro diagnostic industry. They can also be used as diagnostic tools in medicine, as well as being used in several other different industries for various applications. (Lorne Laboratories, 2021) How Does Chemiluminescence Work Chemiluminescence immunoassay (CLIA) is an assay that combines the chemiluminescence techniques with immunochemical reactions. The assay format is similar to enzyme-linked immunoassays, usually based on heterogeneous assays where antibodies or antigens are immobilized on a solid phase but one of the components is conjugated with a chemiluminescent label. (Lorne Laboratories, 2021) (BrightTALK, 2021) CLIA utilizes chemical probes which could generate light emission through a chemical reactions to label the antibody. (Creative-diagnostics, 2021) The Benefits of Chemiluminescence Immunoassay In recent years, CLIA has gained increasing attention in different fields, including life science, clinical diagnosis, environmental monitoring, food safety, and pharmaceutical analysis because there are benefits of using chemiluminescence such as: ultra-sensitive good specificity wide range of applications simple equipment wide linear range easier in operation and design can detect small amounts of the biological molecule does not require long incubations and the addition of stopping reagents (Creative-diagnostics, 2021) Key Types of Chemiluminescent Immunoassay Methods Chemiluminescent methods that have been commonly seen are direct - using luminophore markers, indirect—using enzyme markers, or electrogenerated – typically nanomaterials based. (Cinquanta, Fontana and Bizzaro, 2017) (Ju, Lai and Yan, 2017) Indirect CLIA, using enzyme markers This common CLIA method involves an enzyme, typically horseradish peroxidase (HRP) or alkaline phosphatase (AP), conjugated to a secondary antibody. This HRP– or AP–secondary antibody complex then catalyzes the conversion of chemiluminescent substrate, luminol and CSPD reagent respectively. These substrates, when oxidized, provide an easy means of signal detection and quantification due to prolonged signal emission. (Shimadzu, 2021) Direct CLIA, using luminophore markers This method commonly uses acridinium esters as luminophores conjugated directly to the primary monoclonal antibody to generate a signal. Acridinium esters are highly specific labels that spontaneously oxidiz...

From July 26th to 28th, AACC ANNUAL SCIENTIFIC MEETING CLINICAL LAB EXPO ended successfully. In this exhibition, Xiamen Biotime Biotechnology Co., Ltd. showed multi-scenario in vitro diagnostic solutions, which were recognized and supported by new and old customers. In the future, Xiamen Biotime Biotechnology will continue to provide you with better IVD solutions with high-quality products and services, so stay tuned.

In the Xiamen Trade Fair on 8th Sep. 2021, Xiamen Biotime Biotechnology Co., Ltd. released new drugs development strategy, planning to invest more than 1 billion yuan of scientific research funds in the medical and health field in the next three years, and at the same time set up another 1 billion yuan to focus on investment Funds mainly in the medical and health field. Xiamen Biotime Biotechnology surpassed the IVD boundary and entered the field of new drugs, which attracted the attention of the industry, and quickly reached extensive strategic cooperation with Hangzhou Adlai Nortye Biopharma Co., Ltd. and Shanghai Medicilon Inc. Less than a year, in the beginning of autumn in 2022, Biotime Pharmaceutical (Shanghai) Co., Ltd. was officially put into operation on August 8. At the unveiling ceremony, Yu Jianping, Deputy General Manager, delivered a speech instead of Chief Executive Zhang Guofeng. From Biotime to Biotime Pharmaceutical, from diagnosis to treatment, we have made a big leap. Today we are here to witness an important historical moment of Biotime Pharmaceutical. I believe that with everyone's support, Biotime Pharmaceutical will get a better tomorrow. Afterwards, Lin Baode, head of R&D of Biotime Pharmaceutical, delivered a speech. Today, Biotime Pharmaceutical may be a little spark, but we believe that it will definitely ignite and attract the attention of the industry in the future! Biotime Pharmaceutical Shanghai R&D Center is located on Cailun Road, Zhangjiang High-tech Park, which is known as China Pharmaceutical Valley. The research center that covers an area of about 700 square meters has invested nearly 50 million yuan to configure various high-end precision instruments and equipment, and built a modern laboratory.

WHAT IS CRP C-reactive protein (CRP) is a protein made by the liver. CRP levels in the blood increase when there is a condition causing inflammation somewhere in the body. A CRP test measures the amount of CRP in the blood to detect inflammation due to acute conditions or to monitor the severity of disease in chronic conditions. (LABTESTONLINE, 2021) WHY CRP TEST After an injury, the start of an infection, or other cause of inflammation, CRP is released into the blood within several hours, making it a non-specific indicator of inflammation and one of the most sensitive acute phase reactants. You may need this test if you have symptoms of a serious bacterial infection. The level of CRP can surge as much as a thousand-fold in response to bacterial infection (LABTESTONLINE, 2021) Symptoms include: ²  Fever ²  Chills ²  Rapid breathing ²  Rapid heart rate ²  Nausea and vomiting A CRP test is simple and safe, and you don’t need any special preparations. A health care professional will take a blood sample from a vein in your arm, using a small needle. The process usually takes less than 5 minutes and all you feel is a little sting. (MedlinePlus, 2020) HOW OFTEN SHOULD CRP BE CHECKED Checking the CRP level for the entire adult population is not recommended. Some experts recommend checking the serum CRP level routinely along with the cholesterol level; however, although this is not widely accepted. (MedicineNet, 2021) Ideally, for cardiac risk testing, it is advisable to use the average between two separate CRP levels drawn two weeks part. Because measuring CRP levels at any point in time may be influenced by any infection or inflammation in the body, onetime measurement is generally not regarded as an adequate predictor of cardiovascular risk. (MedicineNet, 2021) CRP MEETS COVID-19 The outbreak of COVID-19 is an emerging global health threat. Clinical studies demonstrated that elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19. It has been found CRP level changes significantly in patients with severe COVID-19 conditions. (MedlinePlus, 2020) With reference to the outcome made by some recent studies, serum concentration of CRP in patients with COVID‐19 are presented in Table 1. (MedlinePlus, 2020) WHY CRP TEST SHOULD BE RECOMMENDED TO THE COVID PATIENTS? Doctors are conducting it mandatorily for the patients with critical conditions who are in hospital care, because it is one of the indicators showing the body’s reaction to the ongoing treatment. In Covid treatment, if the CRP is the normal level then the patient’s body is reacting to the treatment positively and if it is higher than the required, then doctors would check the infection level in the body through other tests like CT scan. CRP test is not costly like CT scan and the CRP level in the patients on the basis of which doctors can decide the next course of action. Doctors recommend it for at least twice on an interval of 4-...

Primary liver cancer is the third leading cause of cancer related death worldwide. Hepatocellular carcinoma (HCC) is the most common (>80%) histological type of liver cancer. There are large variations in geographical distribution of liver cancer worldwide. The disease burden is the highest in areas with endemic hepatitis B virus (HBV) infection, such as in Asian countries, specifically in the East and South-East Asia, while North and South America have a relatively low incidence. About 72% of all liver cancer occurs in Asia, with China accounting for 47% of the global burden. Established risk factors of liver cancer include chronic infection with HBV or hepatitis C virus (HCV), excessive alcohol consumption, nonalcoholic fatty liver disease (NAFLD), and aflatoxin exposure. Carbohydrates Over the past decades, sugar-sweetened beverages (SSB) consumption has increased dramatically worldwide. Although still inconclusive, this rising trend in sugar consumption, practically simple sugar (mainly fructose consumption), has been positively associated with weight gain and obesity, insulin resistance and T2D, and NAFLD. As mentioned above, insulin resistance, obesity and NAFLD may lead to the establishment of HCC. Thus, SSB consumption, mainly fructose, could be thereby linked to HCC development. Dietary fats/fatty acids To date, the association between dietary fat intake and risk of HCC has not been well studied, and the existing epidemiologic evidence is limited and inconclusive. Dietary proteins/amino acids The three BCAAs, leucine, isoleucine and valine, are among the nine essential amino acids for humans. They have been shown to affect gene expression, protein metabolism, apoptosis and regeneration of hepatocytes, and insulin resistance. They have also been shown to inhibit the proliferation of liver cancer cells in vitro.   Dietary trace elements and vitamins In the 2 cohorts of Shanghai Men's and Women's Health Study with 132,765 Chinese adults and over 500 liver cancer cases, it suggested that dietary manganese intake was inversely associated with liver cancer risk Dairy products Previous studies suggested that high dairy product intake may increase the levels of plasma IGF-1. The increased concentration of IGF-1, an important factor in the regulation of cell proliferation, differentiation, apoptosis, and carcinogenesis, might contribute to the development of several cancers including HCC in experimental studies. Fruit, vegetable Consistently, total fiber, vegetable fiber, especially cereal fiber, were possibly associated with lower HCC risk, while fiber from fruit did not seem to be associated with HCC risk. Meats In the Japanese Ministry of Education (JACC) cohort, showing no significant association between beef or pork intake and HCC mortality without adjustment for any risk factors. Intake of red meat particularly processed red meat may increase, while white meat possibly fish may decrease the risk of HCC Coffee and alcohol The evidenc...

Vitamin D For Prevention of Respiratory Tract Infections (COVID-19) What is Vitamin D? Vitamin D is a fat-soluble-vitamin, unlike most other vitamins which are generally obtained through dietary sources, in that a major source derives from UV light-induced conversion of its precursor under the skin which means Vitamin D can be produced by the body itself through exposure to sunlight. Vitamin D is not naturally present in most foods. Dietary sources include fortified foods and supplements. Fatty fish and fish liver oils are among the few quality sources of vitamin D, and smaller amounts are found in beef liver and some mushrooms. (WHO, n.d.) (Lukaszuk and Luebbers, 2017) Studies have shown that there is a high prevalence of vitamin D deficiency worldwide. (WHO, n.d.) Why is Vitamin D Important? Vitamin D deficiency may affect the immune system as vitamin D plays an immunomodulation role, enhancing innate immunity by up-regulating the expression and secretion of antimicrobial peptides, which boosts mucosal defences. Furthermore, recent meta-analyses have reported a protective effect of vitamin D supplementation on respiratory tract infections. (WHO, n.d.) Traditionally, vitamin D deficiency has been associated with rickets, a disease in which the bone tissue doesn't properly mineralize, leading to soft bones and skeletal deformities. But increasingly, research is revealing the importance of vitamin D in protecting against a host of health problems including: l  Increased risk of death from cardiovascular disease l  Cognitive impairment in older adults l  Severe asthma in children l  Cancer (Davis, 2009) Vitamin D Supplementation to Prevent Acute Respiratory Tract Infections Respiratory tract infections are conditions that affect the air passages. These include acute infections that affect the lower respiratory tract and lungs, such as pneumonia and influenza, which are among the leading causes of death in children worldwide. (WHO, n.d.) In 2015, 16% of all deaths in children under five years of age were attributed to pneumonia. Pneumonia is usually caused by a bacterial infection and can also be caused by a virus, such as coronavirus (COVID-19). These conditions may also have an impact on quality of life. Therefore, it is important to find interventions that could prevent respiratory conditions. (WHO, n.d.) A constant effort has been put into addressing those diseases caused by Vitamin D deficiency. And so far to our knowledge, observational studies report consistent independent associations between low serum concentrations of 25-hydroxyvitamin D and susceptibility to acute respiratory tract infection. In a recent-year research conducted by a whole lot of health professionals to find out the role of Vitamin D in preventing respiratory infections, they came to a conclusion: “Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants. And protective effects were seen in those receiv...

On June 6, 2022, the Opening Ceremony of Biotime Academic Exchange Center was successfully held. Associate Dean of Shanghai Academy of Experimental Medicine, President of the National Association of Health Industry and Enterprise Management, Professor Song Haibo, Director of the Fujia Provincial Center For Clinical Laboratory, President of the Fujian Medical Association, Chen Falin, Xiamen University Life Sciences School Professor, Director of the Xiamen University - Biotime Research Center for Translational Medicine Zhang Yongyou and other guests, Chairman of Biotime Zhang Guofeng, Co-CEO Yin Peng, Vice General Manager Huang Jianguo and Zhuang Yanghuang and other business leaders attended the ceremony. Vice General Manager Zhuang Yanghuang led the ceremony Vice General Manager Zhuang said that Biotime Academic Exchange Center is expected to create opportunities and promote exchanges for the experts across the country, and this is also an opportunity for us, to do our best and strive for better future. Professor Song Haibo, President of the Fujian Medical Association Chen Falin, Deputy Director of Xiamen University School of Public Health, Director of the Center for Clinical Laboratories of Xiamen Humanity Hospital, Zhang Zhongying, together with Co-CEO of Biotime Yin Peng officially unveiled the commemorative plaque of the Biotime Academic Exchange Center. Co-CEO of Biotime Yin said that Biotime Academic Exchange Center is a platform at a higher level among leading experts and research communities at university, utilize Biotime’s production capacity to transform R&D achievements into product, as the mission we believe and keep pursuing,“Technology for Health” Director of the Fujian Provincial Center For Clinical Laboratory, President of the Fujian Medical Association, Chen Falin delivers the opening speech On the afternoon of June 6, the 1rst Session of Academic Salon was held.Director Chen said that productivity blends with creativity is a necessity in the development of Medical Laboratory, the establishment of Biotime Academic Exchange Center is to better apply the In-Vitro Diagnostic products into practice. Co-CEO of Biotime Yin Peng shares the trend in Translational Medicine and Biotime’s technology platforms and products Xiamen University Life Sciences School Professor, Director of the Xiamen University - Biotime Research Center for Translational Medicine Zhang Yongyou shares the product development of In-Vitro Diagnostic product with AI-Powered Design Biotime Academic Exchange Center provides a higher level platform for leading experts, exerts its will and capability on In-Vitro Diagnostic industry and takes the lead to construct a sustainable ecosphere and advance the combination of production and product development.